L-dopa level in plasma, primary condition for the kinetic effect
Identifieur interne : 002C83 ( Main/Exploration ); précédent : 002C82; suivant : 002C84L-dopa level in plasma, primary condition for the kinetic effect
Auteurs : W. Birkmayer [Autriche] ; W. Danielcyk [Autriche] ; E. Neumayer [Autriche] ; P. Riederer [Autriche]Source :
- Journal of Neural Transmission [ 0300-9564 ] ; 1973-06-01.
Abstract
Summary: Intravenous or oral application of L-Dopa increased not only the plasma level but led at the same time to an improvement of the kinetic behaviour. A combined intravenous or oral administration of L-Dopa and the decarboxylase inhibitor Ro 4-4602 stop the damage of this peripheral L-Dopa-metabolism for the most part and therefore a higher L-Dopa-plasma-level is reached and the increase lasts longer. A reduction of L-Dopa dosages is the clinical result. A potentiation of clinical and biochemical effects we found in three of ten failures after a medication of L-Dopa plus amantadine-sulfate-infusion. Two of the ten failures showed a clinical deterioration and also diminished L-Dopa-plasma levels after L-Dopa plus amantadine-sulfate-infusions; five of ten failures demonstrated no change in the plasma level after application of amantadine-sulfate-infusions plus L-Dopa. For producing kinetic effects a sufficient availability of L-Dopa in plasma is necessary and a sufficient utilization in the brain has to be. In cases of akinetic crisis a combined infusion of L-Dopa plus amantadine-sulfate is a vital indication.
Url:
DOI: 10.1007/BF01244666
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">L-dopa level in plasma, primary condition for the kinetic effect</title><author><name sortKey="Birkmayer, W" sort="Birkmayer, W" uniqKey="Birkmayer W" first="W." last="Birkmayer">W. Birkmayer</name></author><author><name sortKey="Danielcyk, W" sort="Danielcyk, W" uniqKey="Danielcyk W" first="W." last="Danielcyk">W. Danielcyk</name></author><author><name sortKey="Neumayer, E" sort="Neumayer, E" uniqKey="Neumayer E" first="E." last="Neumayer">E. Neumayer</name></author><author><name sortKey="Riederer, P" sort="Riederer, P" uniqKey="Riederer P" first="P." last="Riederer">P. Riederer</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:09BA74410A97D416A455BA25BFB982AD988806FC</idno><date when="1973" year="1973">1973</date><idno type="doi">10.1007/BF01244666</idno><idno type="url">https://api.istex.fr/document/09BA74410A97D416A455BA25BFB982AD988806FC/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002F36</idno><idno type="wicri:Area/Main/Curation">002B46</idno><idno type="wicri:Area/Main/Exploration">002C83</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">L-dopa level in plasma, primary condition for the kinetic effect</title><author><name sortKey="Birkmayer, W" sort="Birkmayer, W" uniqKey="Birkmayer W" first="W." last="Birkmayer">W. Birkmayer</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Ludwig-Boltzmann-Institut für Neurochemie und Neurologische Abteilung des Alterskrankenhaus der Stadt Wien-Lainz</wicri:regionArea></affiliation></author><author><name sortKey="Danielcyk, W" sort="Danielcyk, W" uniqKey="Danielcyk W" first="W." last="Danielcyk">W. Danielcyk</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Ludwig-Boltzmann-Institut für Neurochemie und Neurologische Abteilung des Alterskrankenhaus der Stadt Wien-Lainz</wicri:regionArea></affiliation></author><author><name sortKey="Neumayer, E" sort="Neumayer, E" uniqKey="Neumayer E" first="E." last="Neumayer">E. Neumayer</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Ludwig-Boltzmann-Institut für Neurochemie und Neurologische Abteilung des Alterskrankenhaus der Stadt Wien-Lainz</wicri:regionArea></affiliation></author><author><name sortKey="Riederer, P" sort="Riederer, P" uniqKey="Riederer P" first="P." last="Riederer">P. Riederer</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Ludwig-Boltzmann-Institut für Neurochemie und Neurologische Abteilung des Alterskrankenhaus der Stadt Wien-Lainz</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neural Transmission</title><title level="j" type="sub">Basic neurosciences and genetics, Parkinson's disease and allied conditions, Alzheimer's disease and related disorders, biological psychiatry</title><title level="j" type="abbrev">J. Neural Transmission</title><idno type="ISSN">0300-9564</idno><idno type="eISSN">1435-1463</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><date type="published" when="1973-06-01">1973-06-01</date><biblScope unit="volume">34</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="133">133</biblScope><biblScope unit="page" to="143">143</biblScope></imprint><idno type="ISSN">0300-9564</idno></series><idno type="istex">09BA74410A97D416A455BA25BFB982AD988806FC</idno><idno type="DOI">10.1007/BF01244666</idno><idno type="ArticleID">Art6</idno><idno type="ArticleID">BF01244666</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0300-9564</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: Intravenous or oral application of L-Dopa increased not only the plasma level but led at the same time to an improvement of the kinetic behaviour. A combined intravenous or oral administration of L-Dopa and the decarboxylase inhibitor Ro 4-4602 stop the damage of this peripheral L-Dopa-metabolism for the most part and therefore a higher L-Dopa-plasma-level is reached and the increase lasts longer. A reduction of L-Dopa dosages is the clinical result. A potentiation of clinical and biochemical effects we found in three of ten failures after a medication of L-Dopa plus amantadine-sulfate-infusion. Two of the ten failures showed a clinical deterioration and also diminished L-Dopa-plasma levels after L-Dopa plus amantadine-sulfate-infusions; five of ten failures demonstrated no change in the plasma level after application of amantadine-sulfate-infusions plus L-Dopa. For producing kinetic effects a sufficient availability of L-Dopa in plasma is necessary and a sufficient utilization in the brain has to be. In cases of akinetic crisis a combined infusion of L-Dopa plus amantadine-sulfate is a vital indication.</div></front></TEI><affiliations><list><country><li>Autriche</li></country></list><tree><country name="Autriche"><noRegion><name sortKey="Birkmayer, W" sort="Birkmayer, W" uniqKey="Birkmayer W" first="W." last="Birkmayer">W. Birkmayer</name></noRegion><name sortKey="Danielcyk, W" sort="Danielcyk, W" uniqKey="Danielcyk W" first="W." last="Danielcyk">W. Danielcyk</name><name sortKey="Neumayer, E" sort="Neumayer, E" uniqKey="Neumayer E" first="E." last="Neumayer">E. Neumayer</name><name sortKey="Riederer, P" sort="Riederer, P" uniqKey="Riederer P" first="P." last="Riederer">P. Riederer</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C83 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C83 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:09BA74410A97D416A455BA25BFB982AD988806FC
|texte= L-dopa level in plasma, primary condition for the kinetic effect
}}
| This area was generated with Dilib version V0.6.23. |  |